Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Oncomatryx will foster its leadership in ADCs targeting the tumor microenvironment. Oncomatryx's pioneering drug OMTX705, which incorporates the cytolysin toxic payload developed by Tube, is a first-in-class ADC targeting cancer-associated fibroblasts.
Lead Product(s): OMTX705,Pembrolizumab
Therapeutic Area: Oncology Product Name: OMTX705
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Tubepharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 18, 2023
Details:
OMTX705 is a pioneering ADC that targets, with a novel, dual mechanism of action, the Cancer-Associated Fibroblasts that enable tumor metastasis, drug resistance and immunosuppression.
Lead Product(s): OMTX705
Therapeutic Area: Oncology Product Name: OMTX705
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
These funds, together with Oncomatryx recurring revenues from its licensing agreements with international biopharmaceutical companies, will be used for the clinical development of additional ADCs of Oncomatryx tumour-microenvironment pipeline including OMTX705.
Lead Product(s): OMTX705
Therapeutic Area: Oncology Product Name: OMTX705
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 22, 2022